Melinda D. Willard

1.4k total citations
27 papers, 478 citations indexed

About

Melinda D. Willard is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Melinda D. Willard has authored 27 papers receiving a total of 478 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 13 papers in Oncology and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Melinda D. Willard's work include Protein Kinase Regulation and GTPase Signaling (9 papers), Colorectal Cancer Treatments and Studies (7 papers) and Lung Cancer Treatments and Mutations (6 papers). Melinda D. Willard is often cited by papers focused on Protein Kinase Regulation and GTPase Signaling (9 papers), Colorectal Cancer Treatments and Studies (7 papers) and Lung Cancer Treatments and Mutations (6 papers). Melinda D. Willard collaborates with scholars based in United States, Japan and France. Melinda D. Willard's co-authors include David P. Siderovski, Francis S. Willard, Adam J. Kimple, Xiaoyan Li, William D. Snider, Steven D. Cappell, Isabella H. Wulur, Christopher A. Johnston, Dustin E. Bosch and Amita Patnaik and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and The EMBO Journal.

In The Last Decade

Melinda D. Willard

25 papers receiving 473 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Melinda D. Willard United States	15	306	144	88	59	49	27	478
Wenliang Li China	12	259 0.8×	88 0.6×	75 0.9×	39 0.7×	62 1.3×	27	423
Madlaina Breuleux Switzerland	8	323 1.1×	154 1.1×	79 0.9×	20 0.3×	25 0.5×	13	486
Jennifer L. Gilmore United States	11	311 1.0×	295 2.0×	89 1.0×	80 1.4×	31 0.6×	13	582
Hong-Jen Lee Taiwan	8	468 1.5×	182 1.3×	54 0.6×	25 0.4×	69 1.4×	8	608
Mi Kyung Park South Korea	15	380 1.2×	187 1.3×	77 0.9×	20 0.3×	106 2.2×	37	604
Wade H. Aaron United States	8	178 0.6×	109 0.8×	29 0.3×	43 0.7×	60 1.2×	18	404
Sylwia Gawrzak Spain	8	232 0.8×	260 1.8×	70 0.8×	21 0.4×	58 1.2×	10	476
Tianjie Pu China	13	203 0.7×	174 1.2×	96 1.1×	34 0.6×	33 0.7×	29	450
Maxime Pinard Canada	10	306 1.0×	112 0.8×	33 0.4×	32 0.5×	49 1.0×	20	499
Ting-Fang Che Taiwan	6	286 0.9×	112 0.8×	67 0.8×	22 0.4×	58 1.2×	10	441

Countries citing papers authored by Melinda D. Willard

Since Specialization

Citations

This map shows the geographic impact of Melinda D. Willard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Melinda D. Willard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Melinda D. Willard more than expected).

Fields of papers citing papers by Melinda D. Willard

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Melinda D. Willard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Melinda D. Willard. The network helps show where Melinda D. Willard may publish in the future.

Co-authorship network of co-authors of Melinda D. Willard

This figure shows the co-authorship network connecting the top 25 collaborators of Melinda D. Willard. A scholar is included among the top collaborators of Melinda D. Willard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Melinda D. Willard. Melinda D. Willard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hollebecque, Antoine, Takafumi Koyama, Yutaka Fujiwara, et al.. (2025). Efficacy and safety of olomorasib, a second-generation KRAS G12C inhibitor, plus cetuximab in KRAS G12C-mutant advanced colorectal cancer.. Journal of Clinical Oncology. 43(16_suppl). 3507–3507.

Burns, Timothy F., Konstantin H. Dragnev, Yutaka Fujiwara, et al.. (2024). Efficacy and safety of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in combination with pembrolizumab in patients with KRAS G12C-mutant advanced NSCLC.. Journal of Clinical Oncology. 42(16_suppl). 8510–8510. 22 indexed citations

Fujiwara, Yutaka, Timothy F. Burns, Konstantin H. Dragnev, et al.. (2024). Efficacy and safety of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in combination with pembrolizumab in patients with KRAS G12C-mutant advanced NSCLC.. Journal of Clinical Oncology. 42(23_suppl). 195–195. 2 indexed citations

Heist, Rebecca S., Takafumi Koyama, Yonina R. Murciano‐Goroff, et al.. (2024). Pan-tumor activity of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in patients with KRAS G12C-mutant advanced solid tumors.. Journal of Clinical Oncology. 42(16_suppl). 3007–3007. 22 indexed citations

Smyth, Emily Nash, Ramón V. Tiu, Melinda D. Willard, et al.. (2023). Clinicogenomic factors and treatment patterns among patients with advanced non–small cell lung cancer with or without brain metastases in the United States. The Oncologist. 28(11). e1075–e1091. 6 indexed citations

Ammakkanavar, Natraj Reddy, Justin Call, Toshio Shimizu, et al.. (2022). Abstract CT202: A first-in-human phase 1 study of LY3537982, a novel, highly selective and potent KRAS G12C inhibitor in patients with KRAS G12C mutant advanced solid tumors (trial in progress). Cancer Research. 82(12_Supplement). CT202–CT202. 1 indexed citations

Alley, Evan, Johanna C. Bendell, Enrica Capelletto, et al.. (2021). Phase 1 cohort expansion study of LY3023414, a dual PI3K/mTOR inhibitor, in patients with advanced mesothelioma. Investigational New Drugs. 39(4). 1081–1088. 19 indexed citations

Kollmannsberger, Christian, Carolyn D. Britten, Anthony J. Olszanski, et al.. (2021). A phase 1 study of LY3076226, a fibroblast growth factor receptor 3 (FGFR3) antibody–drug conjugate, in patients with advanced or metastatic cancer. Investigational New Drugs. 39(6). 1613–1623. 17 indexed citations

Bowman, Lee, Ramón V. Tiu, Emily Nash Smyth, et al.. (2020). Clinical Characteristics, Treatments, and Concurrent Mutations in Non–Small Cell Lung Cancer Patients With NF1 Mutations. Clinical Lung Cancer. 22(1). 32–41.e1. 7 indexed citations

10.

Pant, Shubham, Johanna C. Bendell, Ryan J. Sullivan, et al.. (2019). A phase I dose escalation (DE) study of ERK inhibitor, LY3214996, in advanced (adv) cancer (CA) patients (pts).. Journal of Clinical Oncology. 37(15_suppl). 3001–3001. 19 indexed citations

11.

Schroer, Adam B., Junaith S. Mohamed, Melinda D. Willard, et al.. (2019). A role for Regulator of G protein Signaling-12 (RGS12) in the balance between myoblast proliferation and differentiation. PLoS ONE. 14(8). e0216167–e0216167. 11 indexed citations

12.

Patnaik, Amita, Michael S. Gordon, Frank Tsai, et al.. (2018). A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer. Cancer Chemotherapy and Pharmacology. 82(3). 407–418. 45 indexed citations

13.

Hong, David S., Antoine Hollebecque, Michael S. Gordon, et al.. (2017). A first-in-human dose phase 1 study of LY3009120 in advanced cancer patients.. Journal of Clinical Oncology. 35(15_suppl). 2507–2507. 6 indexed citations

14.

Esseltine, Jessica L., Melinda D. Willard, Isabella H. Wulur, et al.. (2013). Somatic Mutations in GRM1 in Cancer Alter Metabotropic Glutamate Receptor 1 Intracellular Localization and Signaling. Molecular Pharmacology. 83(4). 770–780. 24 indexed citations

15.

Willard, Melinda D., Mary E. Lajiness, Isabella H. Wulur, et al.. (2012). Somatic Mutations in CCK2R Alter Receptor Activity that Promote Oncogenic Phenotypes. Molecular Cancer Research. 10(6). 739–749. 15 indexed citations

16.

Bosch, Dustin E., Francis S. Willard, Ravikrishna Ramanujam, et al.. (2012). A P-loop Mutation in Gα Subunits Prevents Transition to the Active State: Implications for G-protein Signaling in Fungal Pathogenesis. PLoS Pathogens. 8(2). e1002553–e1002553. 30 indexed citations

17.

Willard, Francis S., Melinda D. Willard, Adam J. Kimple, et al.. (2009). Regulator of G-Protein Signaling 14 (RGS14) Is a Selective H-Ras Effector. PLoS ONE. 4(3). e4884–e4884. 39 indexed citations

18.

Johnston, Christopher A., Melinda D. Willard, Adam J. Kimple, David P. Siderovski, & Francis S. Willard. (2008). A sweet cycle for Arabidopsis G-proteins. Plant Signaling & Behavior. 3(12). 1067–1076. 22 indexed citations

19.

Willard, Francis S., Zheng Zhen, Juan Guo, et al.. (2008). A Point Mutation to Gαi Selectively Blocks GoLoco Motif Binding. Journal of Biological Chemistry. 283(52). 36698–36710. 42 indexed citations

20.

Willard, Melinda D., Francis S. Willard, Xiaoyan Li, et al.. (2007). Selective role for RGS12 as a Ras/Raf/MEK scaffold in nerve growth factor‐mediated differentiation. The EMBO Journal. 26(8). 2029–2040. 61 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact